Pascal Ellerbrock

Pascal Ellerbrock currently serves as the Head of Portfolio Coordination & Planning at Boehringer Ingelheim, where he plays a pivotal role in shaping the company's clinical and preclinical research strategies across six diverse disease areas. Leveraging his extensive background in medicinal chemistry, organic synthesis, and pharmaceutical development, Pascal ensures that the company's portfolio aligns with strategic objectives while optimizing resource allocation and investment decisions. His expertise in portfolio management and financial analysis enables him to conduct rigorous investment analyses and performance tracking, fostering high decision quality in the complex landscape of drug development.

In his role, Pascal oversees the coordination of cross-functional teams involved in early-stage research, clinical trials, and regulatory planning, ensuring seamless communication and strategic alignment. His strategic thinking and deep understanding of Arzneimittelentwicklung (drug development) allow him to identify high-potential projects, mitigate risks, and prioritize initiatives that maximize value for both the company and patients. Pascal's unique combination of scientific acumen and strategic training empowers him to evaluate project pipelines holistically, balancing scientific innovation with commercial viability.

Key projects under his leadership include the development of novel therapeutics in immunology and oncology, where he integrates portfolio management tools with financial insights to support data-driven decision-making. His ability to synthesize complex scientific data with strategic and financial considerations makes him a vital contributor to Boehringer Ingelheim’s continued success in bringing innovative medicines to market. Through his work, Pascal exemplifies how strategic thinking, scientific expertise, and financial analysis can converge to optimize pharmaceutical portfolios and accelerate the development of life-changing therapies.